EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Deep Phenotyping of p.(V142I)-Associated Variant Transthyretin Amyloid Cardiomyopathy: Distinct from Wild-Type Transthyretin Amyloidosis?

Yousuf Razvi iD, Adam Ioannou, Rishi K Patel, Liza Chacko, Nina Karia, Mattia Riefolo, Aldostefano Porcari, Muhammad Umaid Rauf, Neasa Starr, Sashiananthan Ganesananthan, Iona Blakeney, Nandita Kaza und 18 weitere

European Journal of Heart Failure · 2024

DOI: 10.1002/ejhf.3088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Yousuf Razvi und 29 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, Division of Medicine, University College London, London, UK. Hauptthemen laut MEDLINE: Cardiomyopathies, Heart Failure, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure. A total of 3–4% of individuals of African descent carry a TTR gene mutation encoding the p.(V142I) variant, a powerful risk factor for development of variant ATTR-CM (ATTRv-CM); this equates to 1.6 million carriers in the United States. We undertook deep phenotyping of p.(V142I)-ATTRv-CM and comparison with wild-type ATTR-CM (ATTRwt-CM). Methods and results A retrospective study of 413 patients with p.(V142I) ATTRv-CM who attended the UK National Amyloidosis Centre (NAC) was conducted. Patients underwent evaluation at time of diagnosis, including clinical, echocardiography, and biomarker analysis; a subgroup had cardiac magnetic resonance (CMR) imaging. A total of 413 patients with ATTRwt-CM, matched for independent predictors of prognosis (age, NAC Stage, decade of first presentation), were used as a comparator group. At time of diagnosis, patients with ATTRv-CM had significant functional impairment by New York Heart Association classification (NHYA class ≥ III; 38%) and 6-min walk test distance (median 276 m). Median 5-year survival in ATTRv-CM patients was 31 versus 59 months in matched patients with ATTRwt-CM (p < 0.001). Patients with ATTRv-CM had significant impairment of functional parameters by echocardiography including biventricular impairment, high burden of regurgitant valvular disease and low cardiac output. Multivariable analysis revealed the prognostic importance of right ventricular dysfunction. CMR and histological analysis revealed myocyte atrophy and widespread myocardial infiltration in ATTRv-CM. Conclusion p.(V142I)-ATTRv-CM has an aggressive phenotype characterized by myocyte loss and widespread myocardial infiltration which may account for frequent biventricular failure and poor prognosis in this ATTR-CM genotypic subgroup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesHeart FailureAmyloid Neuropathies, FamilialHumansPrealbuminRetrospective Studies

Stichwörter der Autor:innen

AmyloidCardiomyopathyTTRTransthyretinV122I

Substanzen

Prealbumin

Autor:innen und Institutionen

  • National Amyloidosis Centre, Division of Medicine, University College London, London, UK.
  • Royal Free Hospital, London, UK.
  • Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy.
  • Imperial College London, London, UK.

ORCID-Profile: Yousuf Razvi

Förderung

  • British Heart Foundation

Zitieren

APA

Razvi, Y., Ioannou, A., Patel, R. K., Chacko, L., Karia, N., Riefolo, M., Porcari, A., Rauf, M. U., Starr, N., Ganesananthan, S., Blakeney, I., Kaza, N., Filisetti, S., Bolhuis, R. E., Rowczenio, D., Gilbertson, J., Hutt, D., Mahmood, S., Lachmann, H. J., …, & Gillmore, J. D. (2024). Deep Phenotyping of p.(V142I)-Associated Variant Transthyretin Amyloid Cardiomyopathy: Distinct from Wild-Type Transthyretin Amyloidosis?. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3088

Vancouver

Razvi Y, Ioannou A, Patel RK, Chacko L, Karia N, Riefolo M, et al. Deep Phenotyping of p.(V142I)-Associated Variant Transthyretin Amyloid Cardiomyopathy: Distinct from Wild-Type Transthyretin Amyloidosis?. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3088

BibTeX
@article{Razvi2024,
  author = {Razvi, Yousuf and Ioannou, Adam and Patel, Rishi K and Chacko, Liza and Karia, Nina and Riefolo, Mattia and Porcari, Aldostefano and Rauf, Muhammad Umaid and Starr, Neasa and Ganesananthan, Sashiananthan and Blakeney, Iona and Kaza, Nandita and Filisetti, Stefano and Bolhuis, Roos Eline and Rowczenio, Dorota and Gilbertson, Janet and Hutt, David and Mahmood, Shameem and Lachmann, Helen J and Wechalekar, Ashutosh D and Kotecha, Tushar and Knight, Daniel S and Coghlan, John G and Petrie, Aviva and Whelan, Carol J and Venneri, Lucia and Martinez-Naharro, Ana and Hawkins, Phillip and Fontana, Marianna and Gillmore, Julian D},
  title = {Deep Phenotyping of p.(V142I)-Associated Variant Transthyretin Amyloid Cardiomyopathy: Distinct from Wild-Type Transthyretin Amyloidosis?},
  journal = {European Journal of Heart Failure},
  year = {2024},
  doi = {10.1002/ejhf.3088}
}
Kostenlos starten →